ARTA
BLRX

A.R.T. Advisors’s BioLineRX BLRX Stock Holding History

A.R.T. Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-28
Closed -$15K – 1411
2018
Q2 		$15K Sell
28
-30
-52% -$15.9K ﹤0.01% 1365
2018
Q1 		$30K Buy
+58
New +$35.5K ﹤0.01% 1427
2017
Q3 		– Sell
-41
Closed -$21K – 1364
2017
Q2 		$21K Buy
+41
New +$21.1K ﹤0.01% 1341
2016
Q3 		– Sell
-43
Closed -$20K – 687
2016
Q2 		$20K Buy
+43
New +$24.1K ﹤0.01% 1300
2014
Q1 		– Sell
-17
Closed -$28K – 1332
2013
Q4 		$28K Buy
+17
New +$27.4K ﹤0.01% 1234

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

A.R.T. Advisors's BLRX Position: Q3 2018 in Review

A.R.T. Advisors sold out of BioLineRX (BLRX) in Q3 2018, closing a stake of 28 shares — an estimated $15K sold.

A.R.T. Advisors first reported a position in BLRX in Q4 2013 and held it in 5 quarters. The position peaked at $30K in Q1 2018. 26 funds tracked by Wall St. Rank hold BLRX as of Q3 2018.

  • A.R.T. Advisors reported no remaining BioLineRX position as of Q3 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 28 BioLineRX shares in Q3 2018, an estimated $15K.
  • A.R.T. Advisors first reported a position in BioLineRX in Q4 2013 and held it in 5 quarters.
  • A.R.T. Advisors's BioLineRX position peaked at $30K in Q1 2018.
  • 26 funds tracked by Wall St. Rank held BioLineRX as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.